Trajectory of Urine Parameters by Adding Herbal Kampo Medicine Goreisan to Tolvaptan in Patients with Congestive Heart Failure
Open Access
- 11 December 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7523
Abstract
Background: Even in current guideline-directed medical therapy, including recently introduced vasopressin type 2 receptor antagonist tolvaptan, congestion has not been resolved in patients with heart failure. Kampo medicine goreisan has been receiving considerable attention as an additional therapy for patients who are refractory to conventional diuretics therapy, including tolvaptan. However, the impact of goreisan on urine electrolytes remains uncertain. Methods: Patients with congestive heart failure who received goreisan as an add-on therapy to tolvaptan-incorporated medical therapy were prospectively included. The changes in urine parameters during the first 24 h were assessed as a primary concern. Baseline factors associated with an increase in urine sodium excretion were investigated. Results: A total of 21 patients were included. The median age was 81 (77, 86), and 13 (62%) were men. Twenty-four hours after the initiation of goreisan, urine osmolality decreased significantly, urine sodium level remained unchanged, urine potassium and glucose levels decreased significantly, urine urea nitrogen level tended to decrease, and urine volume tended to increase. The fractional excretion of sodium tended to increase. Baseline plasma B-type natriuretic peptide level had a positive correlation with a change in fractional excretion of sodium from baseline to day 1 (r = 0.52, p = 0.015). Conclusions: Goreisan may increase urine volume via aquaretic and natriuretic effects in patients with congestive heart failure receiving tolvaptan-incorporated medical therapy. Goreisan may have the ability to “modulate” fluid balance depending on congestion status.Keywords
This publication has 18 references indexed in Scilit:
- Association between complementary use of Goreisan (a Japanese herbal Kampo medicine) and heart failure readmission: A nationwide propensity score-matched studyJournal of Cardiology, 2024
- Short-term impact of kampo goreisan in patients with congestive heart failure refractory to tolvaptan-incorporated medical therapyHeart and Vessels, 2024
- Herbal medicine (Oryeongsan) for fluid and sodium balance in renal cortex of spontaneously hypertensive ratsIntegrative Medicine Research, 2023
- Rationale and study design of the GOREISAN for heart failure (GOREISAN-HF) trial: A randomized clinical trialAmerican Heart Journal, 2023
- Kampo medicine for the holistic approach to older adults with heart failureJournal of Cardiology, 2022
- Diuretic Therapy for Patients With Heart FailureJACC, 2020
- Quantitative evaluation of Oryeongsan and its action on water regulation in renal inner medullary collecting duct cellsJournal of Ethnopharmacology, 2016
- Oryeongsan (Wulingsan), a traditional Chinese herbal medicine, induces natriuresis and diuresis along with an inhibition of the renin–angiotensin–aldosterone system in ratsJournal of Ethnopharmacology, 2012
- Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status TrialsJAMA, 2007
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJAMA, 2007